Continuous Microfluidic Purification of DNA Using Magnetophoresis

Xü, Ying; Zhang, Zhen; Zhou, Xiaoxiang; Han, Xiaoming; Liu, Quanjun

doi:10.3390/mi11020187

Cited by 19 publications

(17 citation statements)

References 35 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NGS enables the analysis of different biomarkers in different patients at the same time and can provide clinically relevant information both before and after targeted treatment, thus assisting treatment decision making in clinical practise ( 158 , 159 ). Microfluidic-based strategies and lab-on-a-chip (LOC) devices for extraction of nucleic acids provide an opportunity for high-throughput screening with reduced sample volume and rapid quantification ( 38 , 160 , 161 ). An overview of current microfluidic technologies for cfDNA isolation and analysis has been recently reported ( 162 ).…”

Section: Circulating Cell-free Dnamentioning

confidence: 99%

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update

et al. 2022

View full text Add to dashboard Cite

Despite efforts to improve earlier diagnosis of non-small cell lung cancer (NSCLC), most patients present with advanced stage disease, which is often associated with poor survival outcomes with only 15% surviving for 5 years from their diagnosis. Tumour tissue biopsy is the current mainstream for cancer diagnosis and prognosis in many parts of the world. However, due to tumour heterogeneity and accessibility issues, liquid biopsy is emerging as a game changer for both cancer diagnosis and prognosis. Liquid biopsy is the analysis of tumour-derived biomarkers in body fluids, which has remarkable advantages over the use of traditional tumour biopsy. Circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) are two main derivatives of liquid biopsy. CTC enumeration and molecular analysis enable monitoring of cancer progression, recurrence, and treatment response earlier than traditional biopsy through a minimally invasive liquid biopsy approach. CTC-derived ex-vivo cultures are essential to understanding CTC biology and their role in metastasis, provide a means for personalized drug testing, and guide treatment selection. Just like CTCs, ctDNA provides opportunity for screening, monitoring, treatment evaluation, and disease surveillance. We present an updated review highlighting the prognostic and therapeutic significance of CTCs and ctDNA in NSCLC.

show abstract

Section: Circulating Cell-free Dnamentioning

confidence: 99%

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Miniaturization of these processes into a single chip may allow for simple and faster methods for extraction of nucleic acids. Thus, several lab-on-a-chip platforms designed to standardize ctDNA detection and characterization have been reported [ 101 , 102 , 103 ]. An overview on current microfluidic technologies for cfDNA isolation and analysis has been reported by Xu et al [ 104 ].…”

Section: Lab-on-a-chip Approaches For Liquid Biopsiesmentioning

confidence: 99%

Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation

Carvalho

Ferreira

Seixas

et al. 2021

Cancers

View full text Add to dashboard Cite

Despite the intensive efforts dedicated to cancer diagnosis and treatment, lung cancer (LCa) remains the leading cause of cancer-related mortality, worldwide. The poor survival rate among lung cancer patients commonly results from diagnosis at late-stage, limitations in characterizing tumor heterogeneity and the lack of non-invasive tools for detection of residual disease and early recurrence. Henceforth, research on liquid biopsies has been increasingly devoted to overcoming these major limitations and improving management of LCa patients. Liquid biopsy is an emerging field that has evolved significantly in recent years due its minimally invasive nature and potential to assess various disease biomarkers. Several strategies for characterization of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have been developed. With the aim of standardizing diagnostic and follow-up practices, microfluidic devices have been introduced to improve biomarkers isolation efficiency and specificity. Nonetheless, implementation of lab-on-a-chip platforms in clinical practice may face some challenges, considering its recent application to liquid biopsies. In this review, recent advances and strategies for the use of liquid biopsies in LCa management are discussed, focusing on high-throughput microfluidic devices applied for CTCs and ctDNA isolation and detection, current clinical validation studies and potential clinical utility.

show abstract

“…(B) Magnetic microfluidic device consists of three branched entry channels into one main channel, then followed with three branched exiting channel, DNA‐carrying beads deflect across the multilaminar flow streams when subjected to external magnetic field generated by a NdFeB magnet. Reproduced with permission from reference [174]. Copyright 2020 MDPI.…”

Section: Microscale Applications Of Magnetophoretic Devicementioning

confidence: 99%

“…The two well‐known and widely used microscale magnetophoretic system, namely magnetic tweezers and magnetophoretic microfluidic system will be the point‐of‐focus of this section. Here, the general features of these two magnetophoretic systems are summarized in Table 1 [133–181].…”

Section: Microscale Applications Of Magnetophoretic Devicementioning

confidence: 99%

Design and operation of magnetophoretic systems at microscale: Device and particle approaches

2021

View full text Add to dashboard Cite

Combining both device and particle designs are the essential concepts to be considered in magnetophoretic system development. Researcher efforts are often dedicated to only one of these design aspects and neglecting the interplay between them. Herein, to bring out importance of the idea of integration between device and particle, we reviewed the working principle of magnetophoretic system (includes both device and particle design concepts). Since, the magnetophoretic force is influenced by both field gradient and magnetization volume, hence, accurate prediction of the magnetophoretic force is relying on the availability of information on both parameters. In device design, we focus on the different strategies used to create localized high‐field gradient. For particle design, we emphasize on the scaling between hydrodynamic size and magnetization volume. Moreover, we also briefly discussed the importance of magnetoshape anisotropy related to particle design aspect of magnetophoretic systems. Next, we illustrated the need for integration between device and particle design using microscale applications of magnetophoretic systems, include magnetic tweezers and microfluidic systems, as our working example. On the basis of our discussion, we highlighted several promising examples of microscale magnetophoretic systems which greatly utilized the interplay between device and particle design. Further, we concluded the review with several factors that possibly resulted in the lack of research efforts related to device and particle design integration.

show abstract

Continuous Microfluidic Purification of DNA Using Magnetophoresis

Cited by 19 publications

References 35 publications

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update

Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation

Design and operation of magnetophoretic systems at microscale: Device and particle approaches

Contact Info

Product

Resources

About